Table 3.

The available treatment modalities, the medications used, and the outcomes of treatment in some studies.

Study	Available treatment modality	Available hormonotherapy drugs	Outcome
Diallo et al. [8]	Surgical ADT (76.3%), medical ADT (22.4%)	Cyproterone acetate	8% castrate resistant
Botcho et al. [9]	Surgical ADT (38.6%), medical ADT, both (18.9%)	Cyproterone acetate, flutamide, LHRH analogue, chemotherapy
Tengue et al. [12]	Surgical ADT (34.5%), medical ADT (12.5%), both (46.1%)	Cyproterone acetate, flutamide	15.1% mortality
Kirakoya et al. [10]	Surgical ADT (24.3%), medical ADT (62.2%), both (13.4%)	Cyproterone acetate, LHRH analogue	10.9% mortality
Kaboré et al. [14]	Surgical ADT (43.3%), medical ADT (19%), both (9.5%)	Cyproterone acetate, LHRH analogue
Wasike and Magoha [15]	Mostly surgical ADT, few medical ADT	Low-dose stilboestrol
Badmus et al. [19]	Surgical ADT (71.9%), medical ADT (24.3%), both (22.2%)	Stilboestrol, bicalutamide, goserelin, flutamide	5-year overall survival (7.4%)
Yeboah et al. [21]	Neoadjuvant hormonotherapy ± medical ADT, EBRT, brachytherapy, TUIP, TURP	Docetaxel, LHRH analogue, stilboestrol, bicalutamide /flutamide	11% hospital mortality
Ekwere and Egbe [13]	Surgical ADT and medical ADT	Stilboestrol	0% 5-year overall survival
Konan et al. [22]	Surgical ADT (86.2%), medical ADT (13.7%)	Cyproterone acetate, LHRH analogue	16.2% mortality
Sow et al. [23]	Group 1: surgical ADT and medical ADT only Group 2: cytoreductive therapy + castration		Group 1: 6-month median (OS) Group 2: 8-month median (OS)

ADT: androgen deprivation therapy; EBRT: external beam radiation therapy; LHRH: luteinizing hormone-releasing hormone; OS: overall survival; TUIP: transurethral incision of the prostate; TURP: transurethral resection of the prostate. Cytoreductive therapy includes open prostatectomy or TURP.